Share Twitter LinkedIn Facebook Email Daniel Goldstein MD Tel Aviv University discusses Moving from Observational Pharmacoeconomics to Interventional Pharmacoeconomics at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia
Genitourinary Cancer [2025] Treatment Breakthroughs: ASCO GU 2025 Highlights Nataliya Mar, MD – MOASC Genitourinary 6 Mins Read
Tivozanib for RCC: Unpacking Efficacy, Safety, and Dose Optimization – Bradley McGregor, MD – Dana Farber Genitourinary 3 Mins Read
Renal Cell Carcinoma TiNivo-2 Study: Patient-Reported Outcomes in Treatment Post-ICI Kidney 3 Mins Read